ArticleBritish journal of haematology2025
Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.
Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.British journal of haematology · 2026Observational
- Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.British journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-refractory acute graft-versus-host disease (SR-aGvHD) remains a significant challenge after haematopoietic cell transplantation (HCT). While ruxolitinib (RUX) has shown efficacy for SR-aGvHD, failure predictors are poorly defined. We assessed 78 patients from six Canadian centres who received RUX for SR-aGvHD. Failure-free survival (FFS) was the primary end-point. Endothelial activation and stress index (EASIX) scores were calculated at defined time points, dichotomized using recursive partitioning. A risk score for RUX failure was developed based on key variables. At RUX initiation, 76% of patients had grade 3-4 aGvHD. The best overall response rate was 75%; 58% experienced RUX failure, while the 6-month FFS was 25.7%. EASIX gradually increased over time even after RUX (p < 0.001). Patients with high EASIX at RUX ≥1.11 had a lower FFS at 6 months (17%) than the patients with low EASIX (54%) (hazard ratio [HR] 2.75 [95%CI 1.23-6.15], p = 0.014). A three-factor RUX failure risk score-gut aGvHD, grade 4 aGvHD and high EASIX at RUX start-stratified patients by 6-month FFS rates: 85.7%, 28.0% and 11.0% for score 0 (n = 28), 1 (n = 25) and ≥2 (n = 34) (HR 2.25[1.42-3.55], p < 0.001). High EASIX can predict the risk of RUX failure in addition to gut aGvHD and grade 4 aGvHD. We propose to add other therapeutic interventions to RUX therapy pre-emptively to high EASIX patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.